Merck Biopharma Korea and LG Chem will comarket Glucophage
By Whang, byung-woo | translator Alice Kang
24.12.12 05:30:31
가나다라
0
Signed an agreement to cooperate on the domestic supply of Glucophage, a treatment for type 2 diabetes
Merck Korea’s quality control capabilities and LG Chem’s sales capabilities to create synergy
▲(from the left) In-Kyum Hwang, Head of the Diabetes and Cardiovascular Business Unit at Merck Biopharma Korea; In-Cheol Hwang, Senior Vice President of LG Chem’s Primary Care Business Division
Merck Biopharma Korea announced on the 11th that it has signed a partnership agreement with LG Chem to jointly sell Glucophage (metformin hydrochloride), a treatment for type 2 diabetes, in Korea.
Under the agreement, LG Chem will distribute Glucophage to healthcare providers in Korea starting January 1, 2025. Merck Biopharma Korea will continue to hold the marketing authorization.
Glucophage is a treatment for type 2 diabetes, a condition in which the body becomes resistant to insulin, resulting in relatively impaired insulin secretion and elevated blood sugar.
Since being first used in the clinic in 1957, it has been in use for more than 60 years and is rec
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)